Fertility preservation for medical reasons in girls and women: British fertility society policy and practice guideline. by Yasmin, E et al.
1 
 
Title  
Fertility preservation for medical reasons in girls and women: British Fertility Society 
Policy and Practice guideline 
 
Authors: on behalf of BFS 
Ephia Yasmina 
Melanie Daviesa 
Georgina Jonesb 
Sheila Lanec 
Raj Mathurd 
Neerujah Balachandrana 
Lisa Webbera 
Richard Andersone  
 
 
a. Department of Women’s Health, University College London Hospitals. London  
b. Department of Psychology, School of Social Sciences, Leeds Beckett University, 
Leeds. 
c. Paediatric Oncology and Haematology, University of Oxford 
d. Department of Reproductive Medicine, Central Manchester University Hospitals 
NHS Foundation Trust, Manchester 
e. MRC Centre for Reproductive Health, Queens Medical Research Institute, 
University of Edinburgh 
 
 
Abstract 
 
Fertility preservation in the female poses several challenges due to the invasive 
nature of the techniques available towards that end. The guideline aims to bring 
together the evidence available for the measures for fertility preservation and their 
outcome. The guideline address fertility preservation for medical reasons and 
includes both oncological and non-oncological causes.  
 
The techniques that the guideline scrutinizes are embryo and oocyte cryo-
preservation, ovarian tissue cryo-preservation, GnRH agonist suppression and 
ovarian transposition. Although ovarian tissue cryo-preservation is still considered 
experimental, the availability of this technique is gaining momentum as more live 
births from auto-transplanted tissue are reported. The guideline also highlights use of 
current treatment modalities for benign and malignant conditions that have a better 
fertility sparing profile. 
 
The guideline recommends multidisciplinary approach in counseling women and girls 
about the risk to their fertility and available techniques. The role of psychological 
support in assisting women and girls with decision making is highlighted. 
 
The guideline also highlights the risks associated with these invasive procedures. 
Patients need to be medically fit to have procedures. Fertility preservation 
techniques are appropriate when treatment has curative intent.  
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Fertility preservation is a subject of ongoing research on outcomes of different 
techniques and at the time of publication, studies are still likely to emerge adding to 
the available literature. 
 
 
Introduction 
Advances in oncology treatments have led to increased survival rates in cancer 
patients. Efforts to minimise the long-term morbidity of treatments and improve 
quality of life among cancer survivors are increasingly a priority. One of the most 
significant late-effects of cancer treatment is the loss of fertility, which is often rated 
as the most distressing outcome of therapy by cancer survivors (Bastings et al., 
2014; Corney and Swinglehurst, 2014; Mancini, et al., 2008 ;  Peate et al.,  2009; 
Ruddy et al., 2014) Given that the average age of first time mothers in the UK is 
continuing to rise (Office of National Statistics, 2016), it is likely that more women will 
be nulliparous at the time of diagnosis of cancer, adding greater focus to the need for 
fertility preservation. Fortunately, techniques used for fertility preservation are 
becoming more established as evidence grows concerning their efficacy and safety. 
 
A number of guidelines pertaining to fertility preservation exist in the worldwide 
literature (Table 1). However comprehensive guidance encompassing all aspects of 
fertility preservation in the female, from counseling to outcome of techniques of fertility 
preservation, would further assist clinicians in this rapidly progressing field. This 
guidance is aimed primarily at clinical practice in the United Kingdom, where provision 
of specific services is subject to regulation by the Human Fertilisation and Embryology 
Authority (HFEA) or the Human Tissue Authority (HTA). 
 
The growing utilisation of fertility preservation by women and the recognition of the 
importance of this in their care by the National Institute of Health and Clinical 
Excellence (NICE), highlights the need for a framework of care for women who are at 
risk of loss of fertility (NICE, 2016). The British Fertility Society first produced a strategy 
for developing policy and practice in fertility services for survivors of cancer in 2003 
(British Fertility Society). Since then the field of fertility preservation has seen 
significant progress. In 2007 a Joint Collegiate working party representing relevant 
professional bodies published ‘The effects of cancer treatment on reproductive 
functions’ (Royal College of Physicians, 2007). The Scottish Intercollegiate Guideline 
Network (SIGN) produced guidance on long-term follow-up of survivors of childhood 
cancer in 2004 and updated this guidance in 2013 (SIGN, 2013). In 2016, the updated 
NICE guidance on fertility included recommendations on fertility preservation (NICE, 
2016). The guidance recommends that discussion about fertility preservation should 
occur early, NHS eligibility criteria for infertility should not be used for women seeking 
fertility preservation, and that no lower age limit should be used.   
 
Aim 
 
This document aims to provide evidence-based guidance to healthcare professionals 
involved in offering and providing fertility preservation to girls and women. 
 
 
 
Scope of the guideline 
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This guideline evaluates the evidence for the different techniques of fertility 
preservation in females. The guideline is aimed at oncologists, haematologists, 
endocrinologists, gynaecologists and all other healthcare professionals such as 
nurses, psychologists, counsellors and general practitioners who play important roles 
in the management of women with cancer considering fertility preservation. 
 
The content of this guideline reflects the fact that the evidence regarding fertility 
preservation is more robust in the post-pubertal age group, but includes current 
options for pre-pubertal girls. In addition, we consider those at risk of premature 
ovarian insufficiency from non-cancer related conditions and individuals transitioning 
from female to male gender. Research recommendations are made to encourage the 
development of evidence in all relevant cohorts. 
 
Elective (‘social’) fertility preservation is outside the remit of the guideline, although 
the technical considerations for oocyte freezing are the same. 
 
 
Background 
 
There are more than 300,000 new cases of cancer every year in the UK (Cancer 
Research UK). The most frequently diagnosed malignancies in women of reproductive 
age are breast cancer, cervical cancer, lymphoma, leukaemia, sarcomas, brain 
tumours, melanomas and ovarian cancer (Miller et al., 2016). 
 
Chemotherapy, radiotherapy and surgical treatments to the ovary may lead to 
reduction or loss of ovarian function with consequent subfertility and premature 
ovarian insufficiency (POI). Novel targeted therapies are increasingly used by 
oncologists, but their impact on reproductive function is largely unknown. The degree 
of damage to gonadal function depends on the type and dose of chemotherapy and 
radiotherapy, the age of the individual and the initial ovarian reserve (Meirow et al., 
2010). Apart from oncology treatments, a broad range of medical conditions requiring 
gonadotoxic therapy may compromise fertility potential: for example, stem cell 
transplantation for benign haematological diseases such as sickle cell anaemia and 
thalassaemia. Surgical therapies for benign gynaecological conditions, such as 
ovarian cystectomy, can also compromise the ovarian reserve. Genetic conditions 
such as Fragile X premutation, mosaicism or monosomy X (Turner Syndrome), 
balanced translocation of the X chromosome and autoimmune conditions may also 
merit consideration for fertility preservation. Fertility preservation in the transgender 
population of transitioning females to males is another area of increasing interest.   
 
 
Although many survivors of childhood cancers will subsequently conceive children 
naturally, higher rates of infertility are reported after some oncology treatments, 
particularly in those who received radiotherapy to the abdomen and pelvis or high 
doses of alkylating agents (Barton et al., 2013, Bramswig et a., 2015) The Childhood 
Cancer Survivor Study cohort shows that the prevalence of subfertility is higher in 
survivors compared with their siblings, even when ovarian function is maintained 
(Barton et al., 2013). Increasingly, more precise data are emerging as to which 
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treatments have significant effects on fertility, and which treatments are associated 
with a better fertility prognosis (Chow et al., 2016).   
 
Embryo cryopreservation has been established in practice for thirty years.  Mature 
oocyte cryopreservation is an alternative option for fertility preservation and is no 
longer experimental (The Practice Committees of the American Society for 
Reproductive Medicine and the Society for Assisted Reproductive Technology 
(ASRM), 2013a). Ovarian tissue cryopreservation is less widely available, particularly 
in the UK, and is still considered experimental, as is in vitro maturation of immature 
oocytes (ASRM, 2013a; ASRM, 2013b).   
 
The likelihood of subsequent utilisation of stored oocytes, embryos or ovarian tissue 
is unknown. Many patients will conceive children naturally, whilst others may not be 
able to use their stored oocytes or embryos. The longer, more extensive experience 
with sperm cryopreservation in oncology suggests that future utilisation of stored 
material is likely to be low (Agarwal et al., 2005 ; Cardozo et al., 2015), and due 
consideration to the management of storage banks is important.  
 
 
Methods 
 
A search of online databases (MEDLINE, EMBASE, Cochrane library and Central 
register of controlled trials) was performed using the keywords:  fertility preservation, 
cancer, oncofertility, oncology, embryo cryopreservation, oocyte cryopreservation, 
ovarian tissue freezing, ovarian transposition, ovarian suppression, GnRH agonists, 
gonadotoxity. Searches were carried out for randomised control trials, systematic 
reviews, existing guidelines, cohorts, case series and case studies until September 
2016. Only English language articles were selected, as resources for translations of 
non-English articles were not available. Peer-reviewed articles, reviews and guidance 
from professional interdisciplinary bodies were included.  Conference abstracts and 
unpublished studies were excluded. The literature search and decisions regarding 
study inclusion were undertaken by all authors, whilst the interpretation of final data 
and quality assessment was undertaken by the co-ordinating author (EY). We 
identified 20 published guidelines from professional bodies (Table 1).  
 
Grading of evidence 
 
The Royal College of Obstetricians and Gynaecologists grading of evidence was 
used (Table 2) 
 
Limitations of available literature 
 
Randomised control trials were lacking for many of the techniques for fertility 
preservation. Cohort studies, small non-randomised trials and case series formed the 
main body of evidence for most of the techniques.  
 
 
Pregnancy outcome in cancer survivors 
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Naturally conceived pregnancies in healthy cancer survivors who were not exposed to 
irradiation are probably at no higher risk than in the general population. There may be 
an increased risk of miscarriage should conception occur within a few months of 
chemotherapy, but not in the longer term (Signorello et al., 2012; Winther et al., 2012). 
In particular, there is no evidence of increased risk of congenital anomalies, even after 
ovarian irradiation or exposure to alkylating agents (Signorello et al., 2012).  
 
Several large population-based studies have examined the outcome of pregnancies 
in survivors of childhood cancer. A British study found that female survivors exposed 
to abdominal irradiation had a significantly increased risk of preterm delivery and low 
birth weight (Reulen et al., 2009) An increased risk of miscarriage was associated with 
abdominal radiotherapy. Live birth amongst survivors were two-thirds lower than 
expected. Mueller et al., (2009) demonstrated similar findings of preterm birth and low 
birth weight from the US Childhood Cancer Survivor Study data. Infants born to 
childhood cancer survivors were more likely to be preterm and have low birth weight. 
However, reassuringly, no increased risks of malformations or infant death was found, 
suggesting no increased germ cell mutation. In a Danish study of 472 survivors of 
childhood and adolescent cancer, no increase in genetic defects was seen in the 
offspring despite mutagenic chemotherapy and radiotherapy doses to the gonads 
(Winther et al., 2012). 
 
Pelvic irradiation (including abdomino-pelvic and spinal irradiation in girls) is 
associated with increased obstetric risks due to poor uterine function, especially when 
exposure occurs before menarche (Bath et al., 1999; Larsen et al., 2004; Signorello 
et al., 2012). These risks include early and late miscarriage, prematurity, low birth 
weight, stillbirth, neonatal haemorrhage, postpartum haemorrhage, and possibly 
uterine rupture and placental attachment disorders such as placenta accreta and 
percreta (Wo and Viswanathan, 2009). 
 
It is outside the scope of this document to consider fully assessment of fitness for 
pregnancy after cancer, the impact of pregnancy on the risk of recurrence, or the 
impact of a recurrence on pregnancy.  However, these issues do need to be 
addressed prior to embarking on pregnancy.  For example, maternal cardiac failure 
precipitated by pregnancy in cancer survivors has been described associated with 
exposure to anthracyclines, high dose cyclophosphamide or cardiac irradiation, which 
may include the scatter from local radiotherapy for breast cancer and not just 
mediastinal irradiation (Appel et al., 2007; Hudson et al., 2010). Pregnancy has not 
been shown to increase the risk of cancer recurrence, including breast cancer, but 
with the exception of trophoblastic disease.  In the UK, these issues will need to be 
considered as part of the statutory Welfare of the Child assessment when a licensed 
fertility treatment is planned (such as transfer of a frozen-thawed embryo or fertilisation 
of frozen-warmed oocytes). 
 
Recommendations:  
 Women should be informed that risk of congenital anomalies or genetic disease 
is not increased after cancer treatment. C 
 Women who received radiotherapy to a field that included the uterus should be 
informed of the obstetric risks. C 
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 Women should be informed that there is no evidence of increased risk of cancer 
recurrence as a result of pregnancy, with most cancers. C 
 
Carriers of BRCA1 gene mutations may have lower ovarian reserve compared with 
age-matched non-carriers (Phillips et al., 2016; Titus et al., 2013). BRCA genes play 
critical roles in the repair of double-stranded DNA breaks. Germline mutations in these 
genes may lead to accelerated oocyte apoptosis and depletion (Wang et al., 2014).  
Markers used to assess the ovarian reserve (AMH, AFC) may be reduced in women 
with cancer, and this may predict a lower response to ovarian stimulation (Phillips et 
al., 2016).  
 
 
Evaluation of the risk of loss of fertility  
 
Many studies have used amenorrhoea as a primary outcome of the effect of cancer 
therapy on fertility. The observed risk of amenorrhoea following various treatments for 
malignancy is listed in Table 3. Amenorrhoea can occur during or shortly after 
completion of radiotherapy or chemotherapy (Jacobson et al., 2015) and may be 
temporary or permanent. However, few studies have had the long-term follow-up 
necessary to diagnose POI with accuracy.  
 
 
Chemotherapy 
 
The risk of infertility is related to the type of chemotherapeutic agent, dose and drug 
regimen and age at time of treatment. Depletion of the pool of primordial follicles and 
compromised vascularity of the gonads are thought to be among the gonadotoxic 
effects of chemotherapy (Morgan et al., 2012). The size of the pre-treatment ovarian 
reserve will also impact on the degree of ovarian toxicity (Anderson and Cameron, 
2011). The gonadotoxity of many chemotherapeutic agents, especially newer ones, 
has not been fully evaluated, and their use in combination also complicates 
assessment of risk. There do not seem to be deleterious long-term effects on the 
genetic competency of surviving oocytes (Signorello et al., 2012; Winther et al., 2012) 
and future pregnancies (Signorello et al., 2006) 
 
 
Recommendation:  
 The risk of infertility, diminished ovarian reserve and premature ovarian 
insufficiency should be assessed based on age, type and dose of 
chemotherapy. C 
 
 
Radiotherapy 
 
The impact of irradiation on the reproductive organs depends on site, dose and age of 
the patient, fractionation of treatment and adjuvant therapy. Abdomino-pelvic radiation 
of 2Gy can cause loss of more than 50% of the primordial pool and radiation doses of 
24Gy will usually cause ovarian failure (Anderson et al., 2015). Cranial irradiation 
causes impairment of hypothalamic–pituitary–gonadal function; radiation doses 
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exceeding 50Gy will usually cause hypogonadism (Gleeson and Shalat, 2005). 
Patients who undergo bone marrow transplantation have extremely high rates of 
ovarian failure, ranging from 72% to 100% after total body irradiation (De Bruin et al., 
2008). The dose of radiotherapy depends on the diagnosis and stage of the disease. 
The typical range of doses of radiotherapy in different conditions is listed in Table 4. 
 
Brachytherapy has significant local effects. Vaginal irradiation leads to dryness, and 
vaginal stenosis. Radiation to the uterus can cause vascular, endometrial and 
myometrial damage leading to tissue fibrosis and restricted uterine capacity and blood 
flow. The ESHRE guideline on premature ovarian insufficiency highlights abnormal 
uterine function and the risk of early and late pregnancy complications in women who 
have received radiotherapy to the uterus (including total body irradiation) (ESHRE, 
2015). The effect on uterine function is dose-dependent and also related to age at the 
time of exposure.  Exposure to radiotherapy before puberty causes significant 
impairment of the development of the uterus (Bath et al., 1999; Larsen et al., 2004) 
and reduced responsiveness to exogenous sex steroids (Critchley et al., 1992).) 
Implications for pregnancy outcome are discussed in the section above on Pregnancy 
outcome in cancer survivors.  
 
 
Recommendation:   
 Patients undergoing pelvic, abdomino-pelvic or cranio-spinal irradiation should 
informed of the risk of infertility, depending on the field of direct and scatter 
exposure C  
 
    
Hormone therapy 
 
Women with hormone-sensitive tumours who are advised to take endocrine therapy 
will have an age-related decline in fertility even if they do not have adjuvant 
chemotherapy and radiotherapy. The recent ATLAS (Adjuvant Tamoxifen: Longer 
Against Shorter) study indicated that 10 years of treatment with tamoxifen is superior 
to a 5-year course, and this will likely result in a larger proportion of breast cancer 
patients needing to further delay childbearing (Davies et al., 2013) .  However, some 
women may choose to take a break from endocrine therapy in order to have a baby, 
after discussion with their oncologist.    
 
Recommendations:  
 The effect of delay in attempting conception due to prolonged endocrine 
therapy after breast cancer should be borne in mind when advising women 
about fertility preservation, even if they do not require gonadotoxic therapy GPP 
 
 
Techniques of fertility preservation 
 
This section discusses established and as yet experimental approaches to 
fertility preservation. It should be recognised that the techniques discussed here do 
not constitute an exhaustive list. In many clinical situations, the patient may have 
recourse to treatment options that have a lesser impact on fertility than other available 
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treatments. This includes, for example, medical treatment with selective progesterone 
receptor modulators and myomectomy rather than hysterectomy for uterine fibroids. 
For any technique, evidence of safety and efficacy in the context of fertility 
preservation is needed before its use for this indication.  
 
Cryopreservation of embryos and oocytes 
 
NICE Guidance recommends embryo and oocyte freezing for fertility preservation 
where a threat exists from oncological treatments or illnesses that compromise fertility 
(NICE, 2016).  
 
Cryopreservation of either oocytes or embryos is preceded by controlled ovarian 
stimulation (COS) and oocyte collection. The possible risks of delay in starting cancer 
treatment should be included in the discussion of these options with patients, and also 
the consequences of any complications of the fertility preservation technique. In 
general, from the start of ovarian stimulation to oocyte retrieval takes approximately 2 
weeks, with chemotherapy usually able to start within 48 hours of egg retrieval.  A 
longer recovery period may be required before surgery and radiotherapy to the pelvis.  
 
 
Recommendations:  
 
Women in the reproductive age range should be offered fertility preservation if: 
 
 there is a material risk of infertility as a result of the intended treatment 
 the treatment for the disease has curative intent or there is good prospect for 
long-term survival 
 the woman is fit for ovarian stimulation and oocyte collection 
 the time required for ovarian stimulation and oocyte collection does not 
jeopardise prognosis.  
GPP 
 
Embryo cryopreservation 
 
The most established technique for fertility preservation is cryopreservation of 
embryos derived from the patient’s oocytes and partner or donor sperm. Embryo 
cryopreservation is suitable for women in a relationship where both partners consent 
to creation and storage of embryos; counseling should address the requirement for 
both partners to consent to the use of embryos in any future fertility treatment. In the 
case of embryos created with donor sperm, future use requires the consent of the 
woman alone. UK clinics providing licensed fertility treatment are obliged to consider 
all factors that may affect the welfare of any child conceived through treatment. 
 
Live birth rates from the transfer of thawed cryopreserved embryos are dependent on 
the age of the woman at the time of oocyte retrieval (HFEA, 2016). It should be noted 
that these data are from subfertile couples undergoing assisted conception, rather 
than couples who have embryos cryopreserved for fertility preservation. The live birth 
rates in women following transfer of pre-chemo/radiotherapy frozen embryos show 
comparable results when compared with age-matched controls, however low rates of 
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utilisation of stored embryos are also observed (Cardozo et al., 2015). Some of the 
causes of non-utilisation are death and ill-health, natural conceptions, and relationship 
breakdown (Barcroft et al., 2013) 
 
Recommendation:  
 Women/couples should be advised that embryo cryopreservation is an 
established technique, with success rates for the transfer of frozen-thawed 
embryos comparable to those for the transfer of fresh embryos  D 
 
 
Oocyte cryopreservation 
 
Women who are not in a relationship, or who do not wish to cryopreserve embryos, 
are offered oocyte cryopreservation. However, the prospect of relationship breakdown 
and inability to use embryos in the future must be borne in mind. For this reason, 
oocyte cryopreservation is an equally important option for women in relationships. The 
development of vitrification has dramatically changed the success of oocyte 
cryopreservation, which is no longer experimental (ASRM, 2013a; NICE, 2016). A 
meta-analysis of the clinical application of oocyte vitrification showed that pregnancy 
rates did not differ between use of vitrified and fresh oocytes, although the study 
population was healthy oocyte donors (Cobo et al., 2013). Indeed, the confidence with 
oocyte cryopreservation derives mainly from experience with cryopreserved donor 
oocytes in recipient cycles (Cobo and Diaz, 2011). In one study, oocyte survival after 
vitrification ranged between 90%–97%, fertilization rates were between 71%-79%, 
clinical pregnancy rates per transfer ranged from 36%-61% and the clinical pregnancy 
rate per thawed oocyte was 4.5%-12% (Cobo and Diaz, 2011 ; Cobo et al., 2016). 
Comparable results have been reported for women whose oocytes were vitrified for 
social fertility preservation, demonstrating that the outcome of oocyte vitrification 
depends on the number and quality of oocytes cryopreserved, and the age of the 
woman at cryopreservation (Doyle et al., 2016) with an overall vitrified-warmed oocyte 
to live-born child efficiency of 6.4% (ASRM, 2013a). Ongoing pregnancy rates in 182 
oocyte vitrification/warming cycles were significantly lower in women over 40 years of 
age compared with younger women (Borini et al., 2006).  
 
Ovarian stimulation and oocyte vitrification can be performed in post-pubertal 
adolescent girls (Lavery et al., 2016) although such interventions in this age group 
raise specific practical and ethical issues, and it is unknown whether the pregnancy 
rate obtained from use of cryopreserved oocytes in this age group is the same as for 
adult women. In the UK, centres performing oocyte retrieval procedures in patients 
under the age of 18 years require specific inspection by the Care Quality 
Commission.   
 
A key benefit of oocyte cryopreservation over embryo cryopreservation is that it 
obviates the need for partner consent to use the stored oocytes in the future. 
 
Recommendation:  
 Women should be advised that oocyte cryopreservation is an effective 
technique, which may have a similar success rate to that using fresh oocytes C 
 
10 
 
 
Controlled ovarian stimulation and oocyte retrieval  
 
Controlled ovarian stimulation (COS) involves administration of exogenous 
gonadotrophins to promote development and maturation of multiple ovarian follicles, 
thereby increasing the number of oocytes available for cryopreservation or generation 
of embryos. 
 
 
Controlled ovarian stimulation regimens 
 
Safe and effective COS and oocyte retrieval for women undergoing fertility 
preservation should take into account the following considerations: 
 
 Minimal delay to treatment: the COS regimen should be applicable without 
delay and aim to elicit a good ovarian response within the shortest possible 
time, thus minimising delay in starting cancer treatment.  
 Ovarian Hyperstimulation Syndrome (OHSS): OHSS may require hospital 
assessment and inpatient care, further delaying the start of cancer treatment. 
Minimising the risk of developing OHSS is therefore of particular significance in 
this group of patients.  Oncology patients may also be at increased risk of VTE 
should OHSS occur. The antagonist protocol with agonist trigger is suitable due 
to the short stimulation to oocyte collection interval and reduced risk of OHSS. 
 Procedural risks: increased risk of haematoma due to thrombocytopenia and 
infection due to neutropenia, secondary to either the underling condition or 
treatments already commenced, should be discussed with the patient and 
appropriate antibiotic cover provided. 
 Anaesthetic risks: patients should be reviewed by an anaesthetist prior to 
oocyte harvest if any risk factors for anaesthesia are present, e.g. mediastinal 
mass in lymphoma patients. 
 Women with pelvic malignancies (e.g. of the cervix or ovary) may be at risk of 
dissemination of malignancy and increased risk of bleeding due to vascularity 
associated with the tumour. It is not known if women with malignancy are at 
increased risk of VTE during or after COS due to the associated increased 
estrogen levels. 
 The route of oocyte collection may have to be altered depending on pelvic 
disease, e.g. abdominal or laparoscopic oocyte collection may be required in 
women with cervical cancers 
 
GnRH antagonist regimens exhibit potential advantages over the use of GnRH agonist 
in fertility preservation, although there have been no comparative trials. Use of GnRH 
antagonist enables ovarian stimulation to be started flexibly at any point in the 
menstrual cycle, thereby minimising delay in treatment. Retrospective studies indicate 
that random-start ovarian stimulation protocols are associated with the collection of 
similar numbers of oocytes, comparable proportions of mature oocytes and similar 
fertilisation rates as conventional early follicular start ovarian stimulation (Cakmak et 
al., 2013).  There are no studies comparing live birth rates with these regimens. In 
addition, the risk of OHSS is lower in treatment cycles using GnRH antagonist 
compared to GnRH agonist. Meta-analysis of 20 trials involving 5141 women 
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undergoing IVF shows a lower rate of moderate or severe OHSS in women receiving 
GnRH antagonist compared with GnRH agonist (Youssef et al., 2011). A further 
advantage of GnRH antagonist regimens is that the pituitary gonadotrophs of women 
receiving GnRH antagonist retain their sensitivity to the initial flare effect of GnRH 
agonist, allowing the use of GnRH agonist to induce final follicular maturation. This 
avoids the use of human chorionic gonadotropin (hCG), which has a longer half-life, 
and hence a greater potential to precipitate OHSS, than endogenous luteinizing 
hormone. Meta-analysis shows that the use of GnRH agonist ‘trigger’ for final follicular 
maturation is associated with a significantly reduced risk of OHSS compared with the 
use of hCG, both in women receiving fresh embryos and in women donating oocytes 
(Youssef et al., 2011). 
 
Evidence is lacking on the type of gonadotropin preparation (recombinant FSH vs 
purified urinary FSH) and the starting dose of FSH specifically in women requiring 
fertility preservation. However, evidence from the wider population of women 
undergoing IVF supports the use of ovarian reserve tests such as serum anti-Mullerian 
hormone (AMH) or antral follicle count (AFC) to determine the starting dose of FSH 
(Jayaprakasan et al., 2012; Nelson et al., 2009). There is evidence to suggest that the 
ovarian response is reduced in women with some cancers (Domingo et al., 2012); 
hence the use of a moderately high dose of FSH is justified for ovarian stimulation in 
these patients.  
 
COS regimens designed specifically to mitigate the effect of elevated oestrogen 
concentrations during ovarian stimulation have been developed for use in women with 
breast cancer. This can be extrapolated to other oestrogen-sensitive cancers. 
Letrozole co-treatment during ovarian stimulation is associated with significantly lower 
oestradiol concentrations compared with conventional gonadotropin stimulation, while 
resulting in similar numbers of oocytes retrieved and cryopreserved (Oktay et al., 
2006). Tamoxifen, a selective oestrogen receptor modulator often used as adjuvant 
treatment for women with hormone-sensitive breast cancer, has been studied as a 
means of managing the potential risk posed by elevated oestradiol concentrations 
during ovarian stimulation in breast cancer.  Meirow et al., (2014) reported outcomes 
of 76 cycles of embryo cryopreservation in women with breast cancer undergoing 
ovarian stimulation with or without concomitant tamoxifen use (Meirow et al., 2014).  A 
recent prospective controlled, non-randomised study in women with Stage 3 or less 
invasive breast cancer showed no increased risk of recurrence in 120 women who 
underwent fertility preservation using letrozole as part of the ovarian stimulation 
protocol, over a mean duration of follow-up of 5 years (Kim et al., 2016). 
 
A meta-analysis by Friedler et al., (2012) indicates that the number of retrieved 
oocytes in women with a cancer diagnosis was significantly lower than in age-matched 
healthy IVF patients (Friedler et al., 2012). Other authors show conflicting data. Quinn 
et al., (2017) demonstrated that response to ovarian stimulation is not impacted by 
breast cancer. In situations where time permits, consecutive cycles of ovarian 
stimulation and oocyte retrieval have been reported with the aim of increasing the 
number of oocytes cryopreserved (Kuang et al., 2014; Turan et al., 2013). This 
approach may be helpful in women who exhibit a poor response to ovarian stimulation 
and in whom the initiation of oncological treatment can be delayed without significant 
adverse effect on prognosis.  
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Recommendations:  
 Antagonist protocols should usually be employed as they shorten the duration 
of treatment and reduce the risk of OHSS. A 
 An agonist trigger in an antagonist cycle should be considered as this 
minimises the risk of OHSS, unless contraindicated A 
 Consider using an anti-oestrogen [letrozole, clomifene or tamoxifen] during 
ovarian stimulation in women with oestrogen-sensitive tumours D 
 
 
Duration of Storage  
 
Data on embryo and sperm storage demonstrate prolonged survival without detriment 
(Di Santo et al., 2012). No differences in survival, fertilisation, cleavage, embryo 
quality, implantation, and live-birth rates were observed in slow-frozen oocytes thawed 
after up to 48 months compared to earlier thaws (Parmegiano et al., 2009). While it 
would seem to be appropriate for the duration of storage to be based on the age of 
the women at the time of treatment, relevant legislation must of necessity be taken 
into account.  In situations where there is actual or anticipated ‘premature infertility’, 
the HF&E Act allows storage of gametes or embryos for a maximum period of 55 
years. Initial storage is for a maximum period of 10 years, and can be extended by 
further 10 year periods (up to the maximum of 55 years) if it is shown at any time within 
each extended storage period that the criterion of premature infertility continues to be 
met. The relevant HFEA consent form is required to be completed by the patient at 
each extension, along with a medical practitioner’s certificate. 
 
When assisted conception with use of the stored oocytes/embryos is planned, the 
welfare of the child assessment will need to be made according to HFEA guidance. 
Patients need to be made aware that subsequent NHS-funding for use of 
oocytes/embryos may depend on meeting criteria for fertility treatment at the time. 
 
Recommendations 
 
 Women/couples should be advised of the length of time their 
oocytes/embryos can be stored and that this limit is statutory. GPP 
 Women/couples should be advised that there is no evidence to indicate that 
the duration of storage influences the success rate of using of thawed 
oocytes/embryos D 
 Welfare of the child assessment should be made at the time of use of 
oocytes/embryos for assisted conception. GPP 
 
Pregnancy outcome using cryopreserved embryos and oocytes 
 
No particular risk has been identified for children born following frozen-thawed embryo 
replacement (Williams et al., 2013). In a large systematic review of pregnancy 
outcome after replacement of frozen-thawed embryos and oocytes, the outcome using 
slow frozen embryos was comparable to that using fresh embryos (Wennerholm et al., 
2009) with no increase in congenital abnormalities. Higher birth weights and lower 
rates of preterm and low birth weights were observed following use of slow frozen 
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embryos compared with children born after fresh IVF/ICS, and no increased risk of 
congenital abnormalities was observed in the analysis of the HFEA data carried out 
by Maheshwari et al., (2016). However, these large population-based studies were 
based on the subfertile population and there is no information specific to the use of 
frozen embryos from cancer patients prior to gonadotoxic treatment. 
 
Recommendation:  
Women/couples can be advised that  
 pregnancy outcome using cryopreserved oocytes/embryos reveals no increase 
in congenital anomalies D 
 current data do not suggest that pregnancy outcomes from oocyte/embryos 
from oncology patients differ from other patients GPP 
 
Ovarian tissue cryopreservation and transplantation  
 
Ovarian tissue cryopreservation (OTC) is the only option for pre-pubertal girls 
(Anderson et al., 2015) and is an option for post-pubertal adolescents and adult 
women particularly when there is a narrow time window for fertility preservation. It has 
the disadvantage of being more invasive, requiring laparoscopy, but successful tissue 
replacement subsequently can restore the endocrine function of the ovary as well as 
fertility (Jensen et al., 2015). Although ovarian tissue cryopreservation is still 
considered experimental, a number of successful pregnancies have been reported 
after orthotopic ovarian tissue transplant with a live birth rate of approximately 25% in 
these series (Donnez et al., 2013, Meirow et al., 2016, Jensen et al., 2015; Van der 
Ven et al., 2016) approximately half of which were natural conceptions and others after 
IVF. Live birth has also been reported after heterotopic replacement (Stern et al., 
2013) although this is generally regarded as much less successful.  Almost all births 
have resulted from tissue that was slow frozen, but births have also been reported 
after ovarian tissue vitrification (Donnez, et al., 2015). There is limited experience in 
application of this technique for restoring fertility when ovarian tissue is cryopreserved 
in adolescence or childhood (Demeestere et al., 2015). 
 
Primordial follicles are located in the ovarian cortex; therefore, obtaining cortical tissue 
potentially enables cryopreservation of significant number of oocytes. Ovarian tissue 
is procured laparoscopically, either by removal of ovarian cortex or unilateral 
oophorectomy. Orthotopic transplantation of ovarian tissue involves transplantation of 
thin, <1.0–1.5 mm thick strips of thawed ovarian tissue into either the medullary portion 
of the remaining ovary or a nearby peritoneal pocket.  
 
Advantages of this technique include the possibility of natural conception as the 
ovarian tissue is in close proximity to the fallopian tube, and importantly the possibility 
of long-term hormone production avoiding the need for hormone replacement therapy. 
Disadvantages include the need for general anaesthesia and laparoscopic surgery, 
and concern about risk of tissue contamination with micrometastatic disease 
especially in haematological malignancies (Dolmans et al., 2013; Jensen et al., 2015). 
To date, there are no case reports of relapse related to re-implanted tissue; however, 
recurrences may occur many years after original disease and it may be difficult to 
establish whether a recurrence was provoked by transplanted tissue.  
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Resumption of normal ovulatory menstrual cycles has been reported in over 90% of 
patients within 4–9 months after transplantation, which is consistent with the time 
necessary to initiate follicular growth and final maturation (Meirow et al., 2015). Grafts 
have been reported to continue functioning for up to 10 years (Jensen et al., 2015; 
Donnez et al., 2015) although this is exceptional, with some grafts showing only very 
short duration of function. 
 
Whilst ovarian tissue cryopreservation techniques are available, in adult patients there 
is no consensus on selection criteria. Most OTC programs have been carried out on a 
research basis, with the use of research criteria. The Edinburgh group published their 
selection criteria (Wallace et al., 2014) based on age (younger than 35 years), no 
previous chemotherapy or radiotherapy (mild or non-gonadotoxic chemotherapy 
acceptable), a realistic chance of surviving for 5 years and a high risk of premature 
ovarian insufficiency (>50%). To date, these are the only validated criteria but there is 
a need to update the criteria based on more recent evidence, for instance the 
availability of accurate measures of ovarian reserve.  Where ovarian reserve is 
reduced, for example with previous chemotherapy, the success from later replacement 
of ovarian tissue may be diminished. Criteria for offering OTC should logically be 
aligned with those for oocyte or embryo cryopreservation.  
 
OTC is still not an established treatment and as such, should only be offered by units 
with relevant clinical and laboratory expertise, protocols and HTA licensing or 
associated with an established unit using a third party arrangement.  NHS Trusts 
also require local governance requirements to be satisfied before a new surgical 
technique is introduced.  
 
 
Recommendations:  
 Ovarian Tissue Cryopreservation can be considered for post-pubertal patients, 
particularly where there is insufficient time for ovarian stimulation and oocyte 
cryopreservation. C 
 Increasing numbers of live births from transplantation of frozen ovarian tissue 
suggests that OTC should be considered for pre-pubertal patients GPP 
 These procedures should only be performed at centres with relevant expertise, 
facilities and HTA licensing. GPP 
 
 
In vitro Maturation  
 
In vitro maturation (IVM) and vitrification of oocytes retrieved from unstimulated 
ovaries is currently considered an experimental technique that can be offered to those 
women who cannot delay their cancer treatment. In oncological patients, oocyte 
maturation rates of 79% and clinical pregnancy rates of 18-30% per embryo transfer 
have been reported with IVM (Hourvitz et al., 2015). Implantation rates are lower 
following transfer of embryos derived from in vitro matured oocytes compared with 
fresh oocytes. It may be possible to combine IVM with ovarian tissue cryobanking (Abir 
et al., 2016).  
 
Recommendation:  
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 IVM should be offered only in specialised units with relevant expertise, 
facilities and HFEA licensing  GPP 
 
 
Ovarian suppression 
 
Suppression of ovarian function by administration of GnRH agonists (GnRHa) 
immediately before and during chemotherapy has been proposed for the preservation 
of ovarian function. One rationale is that destruction of follicles by chemotherapeutic 
agents causes a fall in local anti-Mullerian hormone (AMH) levels; this, with a rise in 
FSH, stimulates more follicles to enter the maturation pathway, rendering them more 
susceptible to the toxic effects of chemotherapy. The rise in FSH is prevented by 
GnRHa. Suppression of follicle growth and reduced ovarian blood flow may also 
contribute, and there is a possibility of direct effects of GnRHa on the ovary.  
 
In recent years, large RCTs have been performed to assess this approach in women 
with early breast cancer. The most recent meta-analysis, including 12 trials (n= 1231 
women) indicated a significant reduction in the risk of ‘premature ovarian failure’ 
(variably defined in the various studies) with OR 0.36, 95%CI 0.23-0.57, although with 
significant heterogeneity. Eight trials reported rates of amenorrhea at 1 year after 
chemotherapy, with OR 0.55, 95%CI 0.41-0.73, without significant heterogeneity 
(Lambertini et al., 2015).  None of the studies have assessed the degree of ovarian 
function ‘saved’ by GnRHa treatment, for example by use of AMH measurements. 
 
The possible clinical benefits from ovarian protection may be increased fertility, or 
reduced impact of estrogen deficiency from delayed POI, although both are likely to 
also be influenced by post-chemotherapy hormone treatments (tamoxifen, ongoing 
ovarian suppression with GnRHa) that may be indicated in these patients. No studies 
have been designed to assess these later outcomes, but the meta-analysis indicates 
that there were more pregnancies in women treated with GnRHa than in those not 
treated. As this was not a primary outcome for any studies, this result should be treated 
with caution. 
 
The majority of studies assessing this approach have been in women with breast 
cancer, although there have been smaller RCTs in women with lymphoma and ovarian 
cancer which did not show a benefit.  These studies were included in an earlier meta-
analysis (Del Mastro et al., 2014), which highlighted the lack of power of studies in 
diseases other than breast cancer.  It remains possible that GnRHa treatment might 
have a beneficial effect in other malignancies (or indeed in other conditions involving 
cytotoxic therapy) and larger RCTs are required to assess this. The most recent trial 
to report in Hodgkin lymphoma found no benefit in terms of POI with GnRHa 
administration although power was low (Demeestere et al., 2016). Whether GnRHa 
administration during treatment impacts survival has been addressed in 3 studies in 
women with breast cancer, and showed no effect (Lambertini et al., 2015). These 
RCTs have used monthly administration of goserelin or triptorelin. GnRH antagonists 
have not been used in RCTs.  
 
An additional benefit of GnRHa administration is suppression of menstruation during 
chemotherapy and the avoidance of heavy menstrual bleeding, which is often due to 
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thrombocytopenia during chemotherapy. The risk is highest at the nadir of 
thrombocytopenia. Menstrual suppression can also be achieved with progestagen. 
GnRHa carries the side-effects of oestrogen-deficiency vasomotor symptoms (hot 
flushes and night sweats) and a risk of osteoporosis. It would seem inappropriate in 
women with hormone sensitive breast cancer to use add-back therapy with low-dose 
estrogen patch or oral tibolone to reduce symptom severity. The initial flare effect of 
GnRHa should be borne in mind when used for menstrual suppression. 
 
Recommendations:  
 In premenopausal women with early breast cancer consider temporary ovarian 
suppression with GnRHa started immediately before and continued during 
chemotherapy as this may partially preserve ovarian function. A  
 Women should be advised that it is possible there is a benefit of using GnRHa 
when other cancers are treated with gonadotoxic chemotherapy. GPP  
 
 
Ovarian transposition 
 
The ovaries can be protected from radiation injury by moving them out of the radiation 
field. This technique is called ovarian transposition, ovarian suspension, oophoropexy, 
or ovariopexy and was introduced more than 50 years ago (McCall et al., 1958) The 
procedure is now performed laparoscopically unless laparotomy is necessary for the 
primary treatment of the tumour (Al-Asari and Abduljabbar, 2012). Techniques for 
ovarian transposition vary according to the radiation field shape, size, and location and 
there are several sites that the ovaries can be moved to (Gershenson, 2005). 
Instances when this may be performed include cervical, rectal and colon cancer, pelvic 
Hodgkin lymphoma and Ewing’s sarcoma (Gershenson, 2005).  
 
Morice et al., reported a series of 24 patients who underwent ovarian transposition to 
the paracolic gutters, before radiation for gynecologic malignancies (Morice et al., 
1998). The authors concluded that this procedure was a safe and effective method of 
preserving ovarian function. Complications are rare in the reported literature. The 
technique involves transposing the ovaries above the pelvic brim and as lateral as 
possible, aiming to minimize the ovarian dose of radiation (Gubbala et al., 2014). The 
ovarian ligament is transected and the ovary mobilised. Blood supply is maintained 
through the infundibulo-pelvic ligament. Attention should be paid to avoid torsion and 
extension of the ovarian vessels which may reduce blood supply to the ovaries, with 
a subsequent effect on ovarian reserve. The ovaries can be marked with metallic clips 
for radiologic identification (Al-Badawi et al., 2010). 
  
Ovarian function after ovarian transposition has been measured by gonadotrophins, 
anti-Mullerian hormone (AMH) and fertility outcomes. Retention of ovarian function 
has been found to be 60-89% after ovarian transposition (Gubbala et al., 2014; 
Falcone et al., 2014), although as all reports are non-randomised the size of the effect 
is unclear. The results may also depend on the type of radiotherapy used (Shou et al., 
2015).  
 
Natural pregnancies are possible if tubal function is preserved as part of the ovarian 
transposition. Morice et al. (1998) reported 16 natural pregnancies after ovarian 
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transposition. In one report of medial ovarian transposition by positioning the ovaries 
behind the uterus in 11 girls with Hodgkin lymphoma, the authors reported 14 
pregnancies over a 15 years follow-up period (Terenziani et al., 2009).  
 
IVF can be carried out following ovarian transposition using abdominal oocyte 
collection. No difference in fertilization and pregnancy rates have been observed with 
trans-vaginally and trans-abdominally collected oocytes (Barton et al., 2011). 
Scattered radiation and reduction in ovarian blood supply after transposition appear to 
be the main factors causing failure of the technique (Crawshaw, 2009). There is a 
small risk of pelvic pain due to the potential for ovarian torsion and fallopian tube 
infarction (Gubbala et al., 2014). 
 
The potential effect of radiation upon the uterus should be borne in mind when 
considering ovarian transposition. Uterine damage from doses in the range of 8500 
cGy or intra-cavitary brachytherapy essentially precludes successful pregnancy, either 
naturally or with in vitro fertilization (Agorastos et al., 2009). Where significant uterine 
damage has occurred, ovarian transposition may allow the patient to retain the 
potential to have biological children with host surrogacy (Agorastos et al., 2009) 
 
 
Recommendation:  
 Consider ovarian transposition to move ovaries away from the field of 
irradiation. D 
 Fallopian tubes should not be transected in order to retain the possibility of 
natural conception.  GPP 
 
 
Shielding of ovaries during radiotherapy 
 
Aside from surgical approaches to protect the ovaries from irradiation, modification of 
radiation techniques to achieve the same end have been explored. External shielding 
is used in an attempt to minimize radiation exposure to ovaries. The entire pelvis 
cannot be blocked from radiation without the potential for also shielding tumour cells 
as well.  Such blocks have been shown to offer poor ovarian protection owing to the 
mobility of the pelvic anatomy (Fawcett et al., 2012). 
 
The use of more complex X-ray planning techniques, such as intensity-modulated 
radiation therapy (IMRT), has also been examined. Although IMRT reduces doses to 
many organs, its capacity to reduce the dose meaningfully for a tissue as 
radiosensitive as the oocyte is quite limited, and ovarian exposure during craniospinal 
irradiation is likely to exceed 3–5 Gy(RBE) even when IMRT is utilized (Pérez-Andújar 
et al., 2013).  
 
Proton therapy is being used for the delivery of craniospinal irradiation in certain 
centres and has been shown to allow reduction in the radiation dose delivered to 
visceral organs anterior to the spinal cord (Yoon, 2012); it may be used for targeted 
pelvic radiotherapy (Fukushima et al., 2015).  Proton beam therapy will be available 
in the UK soon with 2 centres being set up in the country. 
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Recommendation 
 
 Ovarian shielding is of limited use to prevent damage from irradiation and 
generally should not be offered D 
 
 
Fertility-sparing surgery 
 
Fertility-sparing surgery is used in gynaecological cancers with the aim of retaining 
fertility whilst achieving outcomes that are not inferior to more extensive conventional 
surgery. A well-established fertility-sparing surgical procedure in young women with 
early-stage cervical cancer is radical trachelectomy. This may be offered in cases of 
early-stage invasive cervical cancer instead of hysterectomy. A meta-analysis by 
Willows et al., (2016) found that among 1238 patients who underwent fertility-sparing 
surgery for early cervical cancer, 469 pregnancies occurred with a 67 % live birth rate. 
Outcomes after simple trachelectomy or cervical conization were similar. Cervical 
stenosis and subfertility are common after trachelectomy. The risk of recurrence has 
not been found to be higher after these procedures (Okugawa et al., 2016). 
 
In women with borderline ovarian tumours (BOT) concern exists about the effect of 
ovarian stimulation and the risk of microscopic seeding at oocyte collection after 
ovarian cystectomy. Most pregnancies after conservative treatment of BOT are natural 
conceptions. Although BOT are associated with good prognosis, caution needs to be 
exercised because these tumours can relapse and malignant transformation can also 
occur. Nevertheless, the patient should be informed that stimulation treatment may be 
associated with an increased risk of relapse. Cryopreservation of ovarian tissue is 
recommended by certain teams (Fain-Kahn et al., 2009). However, when autologous 
transplant is carried out at a later date for fertility, re-transplantation of borderline tissue 
or the de novo development of a borderline tumour cannot be excluded. 
 
In principle, a pregnancy occurring spontaneously after fertility preservation surgery 
or ovarian stimulation is preferable to cryopreservation of ovarian tissue so that the 
ovarian reserve is not further reduced by the removal of ovarian tissue. Unfortunately, 
evidence about fertility preservation in women with BOT is limited. The patient is 
usually advised to try to conceive spontaneously after fertility sparing surgery. Ovarian 
stimulation and oocyte recovery may be considered after ovarian cystectomy if 
bilateral oophorectomy is planned as a subsequent step and no significant risk has 
been reported (Darai et al, 2013). According to a review of the studies the risk of 
relapse of a borderline tumour after ovarian stimulation treatment was 19.4% without 
resulting in mortality (Denschlag et al., 2010). Letrozole during COH may be 
considered to reduce circulating oestradiol levels. Oocyte retrieval from affected 
ovaries at the time of oophorectomy can be considered with a view to in-vitro 
maturation of oocytes (Mangili et al., 2016). Ovarian tissue cryopreservation is also 
possible although the tissue will only be usable if in vitro culture of oocytes becomes 
available. 
 
Recommendations:  
 Where feasible, fertility-preserving surgery should be considered in selected  
women with gynaecological malignancies  B 
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 Fertility preservation for women with borderline ovarian tumours may be 
associated with additional risks and should be discussed with the patient and 
her oncology team. D 
 
 
Discussion of oocyte donation, surrogacy, adoption 
 
In discussing the effect of cancer and treatment of fertility, alternatives to oocyte, 
embryo and ovarian tissue cryopreservation should be explained. These options 
include oocyte donation and surrogacy, especially where significant radiation damage 
to the uterus is involved, adoption, and life without children. 
 
 
Recommendation: 
Alternatives to fertility preservation should be discussed  GPP 
 
 
Fertility preservation in special conditions  
 
Women at risk of non-iatrogenic premature ovarian insufficiency 
 
A small number of women are at risk of POI due to chromosomal, genetic, or metabolic 
conditions (such as Turner mosaicism, fragile X syndrome (FMR1) carrier status, or 
galactosaemia).  
 
At present, strategies for fertility preservation in post-pubertal girls who are at risk of 
premature ovarian insufficiency (POI) are limited to ovarian tissue cryopreservation 
alone or in combination with immature oocyte collection from the tissue followed by in 
vitro maturation and vitrification of mature oocytes. In addition, patients with Turner 
syndrome, FMR1 carrier status and translocation of X chromosome are candidates for 
Preimplantation Genetic Diagnosis (PGD) (which requires IVF), because of the 
increased risk of fetal chromosomal or genetic abnormalities.  
 
As the majority of women with Turner syndrome have POI, fertility preservation with 
oocyte or ovarian tissue cryopreservation may only be an option for those who have 
spontaneous puberty such as Turner mosaicism (Oktay and Bedoschi, 2014). Almost 
every woman with classic galactosaemia develops POI, although spontaneous 
conception has been described in this condition Gubbels et al., 2009; (van Erven et 
al., 2013). Fertility preservation is only likely to be successful in very young prepubertal 
patients by cryopreservation of ovarian tissue.  
 
 
Benign conditions treated with chemotherapy  
 
Some non-malignant diseases may require treatments that can impact reproductive 
function. In patients with systemic lupus erythematosus (SLE), the predominant 
mechanism of infertility is related to medication rather than disease. The incidence of 
amenorrhea following cyclophosphamide treatment for SLE ranges from 27% to 60% 
(Katsifis & Tzioufas, 2004). 
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A variety of disorders may be treated with bone marrow transplantation or 
haematopoietic stem cell transplant with preconditioning alkylating chemotherapy with 
or without radiation, including thalassemia major, sickle cell anaemia, aplastic 
anaemia, Fanconi anaemia, and myeloproliferative diseases (Gidoni et al., 2008; Tan 
et al., 2006). The combination of radiation and high-dose chemotherapy required 
before bone marrow transplant makes recovery of ovarian function in this patient 
population unlikely, and spontaneous recovery of ovarian function, as defined by a 
return of menstrual cycles, has been found to occur in only 6% of patients 
(Griessahmmer et al., 1998).  Some of these conditions (eg sickle cell disease) will 
themselves affect ovarian reserve and may reduce the number of oocytes collected, 
should FP be undertaken. In children and young adults, ovarian tissue 
cryopreservation should also be considered for this group of patients (Lavery et al., 
2016). 
 
 
Pelvic surgery  
 
Surgery for endometriomas, large ovarian dermoid cysts, and recurrent benign ovarian 
cysts is also likely to reduce ovarian reserve. Therefore women at risk of recurrent 
ovarian cystectomies should have a discussion about the effect of repeated surgery 
and the option of oocyte and embryo cryopreservation should be discussed. 
 
 
Recommendations 
 Discuss fertility preservation options with girls and women at risk of premature 
ovarian insufficiency from non-malignant conditions GPP 
 Advise women and girls that the evidence for the success of fertility 
preservation for these indications is limited. GPP 
 
 
Individuals transitioning from female to male gender  
 
The implications for fertility should be discussed with individuals transitioning from 
female to male gender. The treatment pathway may include administration of GnRHa 
to suppress the hypothalamic-pituitary ovarian axis in young people and testosterone 
to induce virilisation, with finally oophorectomy with or without hysterectomy. To retain 
the possibility of becoming a genetic or biological parent, individuals may wish to store 
gametes, and may decide to postpone sterilising surgery. Duration of storage will be 
the same as for other medical indications. 
 
Fertility preservation should be discussed and, if appropriate, carried out as early as 
possible in this pathway. Oocyte freezing is likely to be the appropriate mode of fertility 
preservation. The practicalities of regrafting make it unlikely that OTC would be a 
viable option in these cases. 
 
There is no report of fertility preservation after testosterone has been given to induce 
virilisation. Although low doses of androgens have been described as an adjunct to 
ovarian stimulation (Nagels et al., 2015), it is not known whether ovarian stimulation 
Commented [LT6]: Consider adding multiple sclerosis? 
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and collection of competent oocytes is possible after high doses of androgens 
prescribed for virilisation. 
 
Counselling is strongly recommended in this complex situation; it should also cover 
the potential use of stored material following transition, i.e. whether the individual 
would be prepared to carry a pregnancy in the future, or whether surrogacy would be 
required. 
 
Recommendations 
 
 Discuss fertility preservation with people transitioning from female to male 
gender GPP 
 If appropriate, fertility preservation should be performed as early as possible 
in the treatment pathway GPP 
 Offer counselling, both prior to fertility preservation and prior to use of stored 
material GPP 
 
Timing of discussion on fertility preservation 
 
It is generally agreed that women with cancer should be given detailed information 
about the threat that cancer treatment poses to fertility as early as possible in the 
cancer treatment pathway (De Vos et al., 2014). The optimal time for FP information 
appears to be shortly after cancer diagnosis and during the cancer treatment planning 
stage, specifically before the FP consultation appointment (Balthazar et al., 2011; 
Garvelink et al., 2015). Information should be provided by both the referring oncologist 
and fertility team. 
 
 
Counselling and psychological support in fertility preservation 
 
There is ample evidence that women of reproductive age with cancer have significant 
concerns about the effect of cancer treatment on their fertility and the means by which 
they can preserve it (Peate et al., 2012; Tschudin and Bitzer, 2009). The potential to 
have biological children appears to be high on their list of priorities (Peate et al., 2012).  
Women find themselves in a situation where they have to come to terms with their 
diagnosis and make decisions about their cancer and fertility preservation treatments 
in a very short period of time. This can be a source of distress and anxiety. However, 
the provision of guidance for psychological support is difficult because the decision-
making process is often complex and hindered by a number of factors with little 
evidence of psychological interventions that may help support women through the 
fertility preservation process.  
 
Supporting patients to make decisions about their future fertility depends on a 
multidisciplinary approach involving clinical, nursing and surgical teams, psychologists 
and counsellors. Women often express many fears and anxieties, for example, over 
the implications of pursuing fertility preservation alongside cancer diagnosis/cancer 
recurrence and the potential health of a future child (Wilkes et al., 2010). A discussion 
about fertility preservation with a trained counsellor is advocated in existing clinical 
guidelines (Loren et al., 2013) although many patients do not appear to get access to 
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this type of service (Letourneau et al., 2011; Niemasik et al, 2012). Evidence suggests 
that many women feel that they do not have access to information that would support 
them with their decision-making and feel ‘too rushed’ in consultations to initiate or have 
the fertility discussion (Jones et at., 2016a; Jones et al., 2017; Woodruff et al., 2014). 
It is therefore important that women are given high quality information and the time 
needed to absorb this information. 
  
Consideration should be paid to the woman’s religious or cultural beliefs and individual 
values. When dealing with adolescent or pre-pubertal girls, identifying these 
separately from the wishes of family members can be challenging but the patient’s 
autonomy should be preserved where possible (Tschudin et al., 2010).  
 
Many women will experience cancer after having children. The decisional issues for 
women starting or completing their family are different. 
 
Decision support interventions help patients think about the choices they face in ways 
which will help inform decision-making (Elwyn et al, 2012). Patient decision aids are 
one such example of a decision support intervention. Their aim is to support people to 
make decisions between healthcare options.  Several patient decision aids exist to 
support the fertility preservation process for women (Peate et al., 2012). Two are 
specifically for women of reproductive age with a breast cancer diagnosis (Peate et 
al., 2012; Garvelink et al, 2013). They have undergone more extensive evaluation and 
have been found to reduce decisional conflict and regret about the decision made and 
increase FP knowledge. Recently, a new tool to support teenage and adult women 
with any cancer to make fertility preservation decisions has become available, 
although it is still in the early stages of evaluation (Jones et al., 2017b).  
 
Decisional conflict appears to be lower when fertility preservation is funded compared 
with when it is not (Mersereau et al., 2013).  Surveys of oncologists have found that 
many express the need for more fertility preservation information to enable them to 
support women more effectively (Adams et al., 2013), The implementation of other 
decision support interventions such as more education and training packages may 
therefore prove beneficial. In particular, those targeted at improving the 
communication skills needed to improve collaborative decision-making between 
patient and provider to deliver care that is patient-centred. 
 
The role of psychology and counseling extends beyond decision-making. Ongoing 
support needs to be available when patients experience the late effects of cancer 
treatment and deal with infertility.  
 
Recommendations 
 Discuss fertility preservation as early as possible in the cancer treatment 
pathway C 
 Refer women to a trained counsellor, both prior to fertility preservation and 
prior to use of stored material GPP 
 Decision making aids should be provided to support women’s fertility 
preservation decision-making, ideally at cancer diagnosis/treatment planning. 
GPP 
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Summary of recommendations 
 
The fertility preservation techniques are summarized in table 5 
 
 
 Women should be informed that risk of congenital anomalies or genetic disease 
is not increased after cancer treatment. C 
 Women who received radiotherapy to a field that included the uterus should be 
informed of the obstetric risks. C 
 Women should be informed that there is no evidence of increased risk of cancer 
recurrence as a result of pregnancy, with most cancers. C 
 The risk of infertility, diminished ovarian reserve and premature ovarian 
insufficiency should be assessed based on age, type and dose of 
chemotherapy. C 
 Patients undergoing pelvic, abdomino-pelvic  or cranio-spinal irradiation 
should informed of the risk of infertility, depending on the field of direct and 
scatter exposure C  
 The effect of delay in attempting conception due to prolonged endocrine 
therapy after breast cancer should be borne in mind when advising women 
about fertility preservation, even if they do not require gonadotoxic therapy GPP 
 
Women in the reproductive age range should be offered fertility preservation if: 
 there is a material risk of infertility as a result of the intended treatment 
 the treatment for the disease has curative intent or there is good prospect for 
long-term survival 
 the woman is fit for ovarian stimulation and oocyte collection 
 the time required for ovarian stimulation and oocyte collection does not 
jeopardise prognosis. GPP 
 
 Women/couples should be advised that embryo cryopreservation is an 
established technique, with success rates for the transfer of frozen-thawed 
embryos comparable to those for the transfer of fresh embryos  D 
 
 Women should be advised that oocyte cryopreservation is an effective 
technique, which may have a similar success rate to that using fresh oocytes C 
 Antagonist protocols should usually be employed as they shorten the duration 
of treatment and reduce the risk of OHSS. A 
 An agonist trigger in an antagonist cycle should be considered as this 
minimises the risk of OHSS, unless contraindicated A 
 Consider using an anti-oestrogen [letrozole, clomifene or tamoxifen] during 
ovarian stimulation in women with oestrogen-sensitive tumours D 
 Women/couples should be advised of the length of time their 
oocytes/embryos can be stored and that this limit is statutory. GPP 
24 
 
 Women/couples should be advised that there is no evidence to indicate that 
the duration of storage influences the success rate of using cryopreserved 
and warmed oocytes/embryos D 
 Welfare of the child assessment should be made at the time of use of 
oocytes/embryos for assisted conception. GPP 
 
Women/couples can be advised that  
 pregnancy outcome using cryopreserved oocytes/embryos reveals no increase 
in congenital anomalies D 
 current data do not suggest that pregnancy outcomes from oocyte/embryos 
from oncology patients differ from other patients GPP 
 
 Ovarian tissue cryopreservation (OTC) can be considered for post-pubertal 
patients, particularly where there is insufficient time for ovarian stimulation and 
oocyte cryopreservation. C 
 Increasing numbers of live births from transplantation of frozen ovarian tissue 
suggests that OTC should be considered for pre-pubertal patients GPP 
 
 These procedures should only be performed at centres with relevant expertise, 
facilities and HTA licensing. GPP 
 IVM should be offered only in specialised units with relevant expertise, facilities 
and HFEA licensing  GPP 
 In premenopausal women with early breast cancer consider temporary ovarian 
suppression with GnRHa started immediately before and continued during 
chemotherapy as this may partially preserve ovarian function. A  
 Women should be advised that it is possible there is a benefit of using GnRHa 
when other cancers are treated with gonadotoxic chemotherapy. GPP  
 Consider ovarian transposition to move ovaries away from the field of 
irradiation. D 
 Fallopian tubes should not be transected during ovarian transposition in order 
to retain the possibility of natural conception.  GPP 
 Ovarian shielding is of limited use to prevent damage from irradiation and 
generally should not be offered D 
 Where feasible, fertility-preserving surgery should be considered in selected 
women with gynaecological malignancies  B 
 Fertility preservation for women with borderline ovarian tumours may be 
associated with additional risks and should be discussed with the patient and 
her oncology team. D 
 Alternatives to fertility preservation should be discussed  GPP 
 Discuss fertility preservation options with girls and women at risk of premature 
ovarian insufficiency from non-malignant conditions GPP 
 Advise women and girls that the evidence for the success of fertility 
preservation for these indications is limited. GPP 
 
 Discuss fertility preservation with people transitioning from female to male 
gender GPP 
 If appropriate, fertility preservation should be performed as early as possible 
in the treatment pathway GPP 
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 Offer counselling, both prior to fertility preservation and prior to use of stored 
material GPP 
 Discuss fertility preservation as early as possible in the cancer treatment 
pathway C 
 Offer counselling, both prior to fertility preservation and prior to use of stored 
material D 
 Resources embedded within a decision support intervention framework (such 
as a patient decision aid) should be provided to support women’s fertility 
preservation decision-making, ideally at cancer diagnosis/treatment planning. 
GPP 
 
 
 
Service organisation 
 
Fertility Preservation services should be organised around efficient pathways enabling 
patients to access the appropriate expertise and treatment in a timely and supportive 
manner. Local needs and resources should dictate the specific pathways agreed, but 
close co-operation between relevant disciplines and a patient-centred approach is key. 
Pathway development requires liaison between the likely sources of referral (such as 
Oncology and Haematology) and the centres where fertility preservation treatment is 
carried out. Owing to the time-critical nature of cases, service commissioners should 
be involved to obtain agreement on funding mechanisms. Patients should be offered 
follow up in the fertility clinic to advise them of the late effects, provide management 
and discuss options for fertility. 
 
Embryo and gamete cryopreservation facilities are available in most assisted 
conception units, which are regulated in the UK by the Human Fertilisation and 
Embryology Authority (HFEA). Gonadal tissue cryopreservation requires access to 
Human Tissue Authority (HTA)-licensed storage facilities. Any centre providing care 
to individuals under the age of 18 must meet specific Care Quality Commission or 
HFEA requirements.  
 
 
 
Recommendations for audit 
 
Audit is essential to monitor and improve the quality of care provided to patients who 
may require fertility preservation. The paucity of agreed standards is a difficulty that 
needs to be addressed. There is a role for deriving standards from research. 
Professional organisations such as the Fertility Preservation Network, a Special 
Interest Group within the British Fertility Society, may have a role in developing 
standards based on surveys of practice and the opinions of clinicians and service 
users. 
 
Useful areas for audit may include the following: 
 the proportion of cancer sufferers offered fertility preservation advice in the 
relevant age group 
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 proportion of cancer sufferers in whom ovarian reserve is measured before and 
after cancer treatment 
 the uptake of fertility preservation treatment in the relevant age group and 
among patients offered this option 
 proportion of patients offered access to evidence-based patient decision aids 
 time from cancer diagnosis to fertility preservation procedure.  
 
The creation of a central registry in the UK for fertility preservation would be a powerful 
tool to guide future audit and research. At present, licensed treatments for fertility 
preservation (embryo and oocyte storage) are regulated by and reported to the HFEA, 
but the data available are limited. Distinguishing between fertility preservation by 
indication (cancer diagnosis versus infertility or ‘social’) would be an important first 
step to collecting usable data. 
 
 
 
Areas for research  
 
This guideline identifies several areas in fertility preservation that require data and 
information. Some such areas are- 
 
Prediction of ovarian damage, risk stratification, accurate identification of risk 
 
Cohort studies with documentation of pre-treatment parameters (e.g., age and AMH) 
and treatment given 
 
Research in ovarian tissue technologies – risk of re-grafting, micro-metastases and 
new methods of identifying contaminated tissue  
 
Decision-making in fertility preservation 
 
 
 
Conclusions:  
 
Challenges in fertility preservation for women with cancer and other conditions include 
the distress and vulnerability, the paucity of time, limited quality of evidence for some 
techniques, and the variation in access to fertility preservation techniques and funding. 
In some situations, the risk of treatment-related infertility can be difficult to estimate 
due to the use of new therapies for which there are limited data only. Where the overall 
risk of infertility is low, patients should be counselled appropriately so that there is no 
delay to cancer treatment. It is important to emphasise that although some treatments 
are non-sterilising, they have the potential to reduce fertility and the reproductive 
lifespan. Moreover, patients may also require gonadotoxic therapy due to relapse of 
disease after previous treatment with a regimen with low gonadotoxic therapy.  
 
The field of fertility preservation is evolving rapidly and practice will change as the 
evidence base worldwide develops.  
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with fertility 
problems. 
Clinical 
guideline 156 
NICE 2013 UK 
20 Scottish 
Intercollegiat
e Guidelines 
Network 
SIGN Long term 
follow up of 
survivors of 
childhood 
cancer 
SIGN 2013 UK 
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Table 2. The Royal College of Obstetricians and Gynaecologists Grading of evidence 
 
Classification of evidence levels Grades of recommendations 
1++ High-quality meta-analyses, systematic 
reviews of randomised controlled trials or 
randomised controlled trials with a very low 
risk of bias 
 
1+ Well-conducted meta-analyses, 
systematic reviews of randomised 
controlled trials or randomised controlled 
trials with a low risk of bias 
 
1− Meta-analyses, systematic reviews of 
randomised controlled trials or randomised 
controlled trials with a high risk of bias 
 
A. At least one meta-analysis, systematic 
reviews or randomised controlled trial rated 
as 1++, and directly applicable to the target 
population; or A systematic review of 
randomised controlled trials or a body of 
evidence consisting principally of studies 
rated as 1+, directly applicable to the target 
population and demonstrating overall 
consistency of results 
 
2++ High-quality systematic reviews of 
case–control or cohort studies or high-
quality case–control or cohort studies with a 
very low risk of confounding, bias or chance 
and a high probability that the relationship 
is causal 
 
2+ Well-conducted case–control or cohort 
studies with a low risk of confounding, bias 
or chance and a moderate probability that 
the relationship is causal 
 
2− Case–control or cohort studies with a 
high risk of confounding, bias or chance 
and a significant risk that the relationship is 
not causal 
B. A body of evidence including studies 
rated as 2++ directly applicable to the target 
population, and demonstrating overall 
consistency of results; or Extrapolated 
evidence from studies rated as 1++ or 1+ 
 
3 Non-analytical studies, e.g. case reports, 
case series 
 
C. A body of evidence including studies 
rated as 2+ directly applicable to the target 
population, and demonstrating overall 
consistency of results; or Extrapolated 
evidence from studies rated as 2++ 
 
4 Expert opinion D. Evidence level 3 or 4; or Extrapolated 
evidence from studies rated as 2+” 
 
 
 
 
 
Table 3. Risk of amenorrhoea after oncology therapy adapted from ASCO guidelines 
2013 (http://ascopubs.org/doi/abs/10.1200/JCO.2013.49.2678) 
 
Degree of risk Treatment protocol Dose Conditions 
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High risk 
(>70% risk of 
amenorrhoea) 
Stem cell transplant with 
total body irradiation  
 leukemia 
lymphoma 
haemoglobinopathies 
brain tumours in 
children 
Whole abdominal or pelvic 
radiation doses  
> 6 Gy in 
adult women  
> 10 Gy in 
post-pubertal 
girls 
> 15 Gy in 
pre-pubertal 
girls  
Wilms’ tumour, 
neuroblastoma, 
sarcoma,  
Hodgkin’s lymphoma 
alkylating agents: 
 busulphan 
 chlorambucil 
 chlormethamine 
 cyclophosphamide 
 ifosfamide 
 Lomustin 
 melphalan 
 procarbazine 
 
Total cyclophosphamide 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 g/m
2 
in 
women age > 
40 
7.5 g/m
2 
in 
women and 
girls age <20  
Breast cancer 
NHL 
Conditioning for 
HSCT 
Protocols containing 
procarbazine 
MOPP 
BEACOPP 
 
 
 
> 3 cycles  
> 6 cycles  
Hodgkin’s lymphoma 
Intermediate 
risk 
(30-70%) 
Total cyclophosphamide 5g/m in 
women 30-
40yrs 
Breast 
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AC for breast cancer X4+paclitaxel 
or doxacetal 
in women 
>40yrs 
Breast 
Monoclonal antibodies  Colon 
Non-small cell lung 
Head and neck 
breast 
Cisplatin  cervical 
Abdominal/pelvic irradiation 10-15Gy in 
pre-pubertal 
girls 
5-10 Gy in 
post pubertal 
girls 
Wilms’ Tumour 
Neuroblastoma 
Spinal tumours 
Brain tumours 
Relapsed ALL, NHL 
Lower risk 
(<30%) 
Protocols containing non-
alkylating agents or lower 
doses of alkylating agents 
ABVD 
CHOP 
COP 
 Hodgkin 
Non-Hodgkin 
Leukaemia 
Anthracycline and 
cytarabine 
 AML 
Very low/no 
risk 
Radioactive iodine  Thyroid 
Multi-agent therapies with 
vincristine 
 Leukaemia 
Lymphoma 
Breast 
lung 
 Methotrexate  GTD 
Unknown Monoclonal antibodies- 
Cetuximab 
Trastuzamab 
 Colon 
Lung 
Head and neck 
breast 
Taxanes   
Tyrosine kinase inhibitors  CML, GIST 
PARP inhibitors  breast 
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AC- Adriamycin and Cyclophosphamide    
 
ABVD- 
A – doxorubicin (Adriamycin ®) 
B – bleomycin 
V – vinblastine (Velbe ®) 
D – dacarbazine (DTIC) 
 
BEACOP 
B – Bleomycin 
E – Etoposide 
A – Doxorubicin ( Adriamycin) 
C – Cyclophosphamide 
O – Vincristine ( Oncovin) 
P – Procarbazine 
P – Prednisolone  
 
CHOP 
C = Cyclophosphamide 
H = Doxorubicin Hydrochloride ( Adriamycin) 
O = Vincristine (Oncovin) 
P = Prednisolone  
 
COP 
Cyclophosphamide 
Vincristine 
Prednisolone 
 
HSCT- Haemopoetic stem cell transplant 
1. GIST-gastro-intestinal stromal tumour0.1245/s10434-010-0935-1 
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Table 4. Doses of irradiation in common cancers  
Type of cancer Dose 
Hodgkin’s lymphoma 20-40 Gy 
Non-Hodgkin’s 
lymphoma 
30 Gy 
NK/T Cell lymphoma 50Gy 
Soft tissue sarcoma 
50 – 
66Gy 
Skin cancers  18-60Gy 
 
 
 
 
  
Table 5. Fertility preservation strategies in females 
Cryopreservation Surgical  Medical Delivery of radiation 
Embryo cryopreservation  
Ovarian 
transposition 
GnRH agonist 
suppression 
Shielding of ovaries 
Oocyte cryopreservation  
Fertility-sparing 
surgery 
 
Intensity modulated 
radiotherapy 
Ovarian tissue 
cryopreservation (OTC) 
  Proton beam therapy 
OTC with in vitro maturation 
of oocytes (IVM) 
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